SEARCH

SEARCH BY CITATION

References

  • 1
    Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 2004; 328:7504.
  • 2
    Lindley S, Dayan CM, Bishop A et al. Defective suppressor function in CD4(+) CD25(+) T-cell from patients with type 1 diabetes. Diabetes 2005; 54:929.
  • 3
    Peng Y, Laouar Y, Li MO et al. TGF-β regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004; 101:45727.
  • 4
    Marie JC, Letterio JJ, Gavin M et al. TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005; 201:10617.
  • 5
    Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:44785.
  • 6
    Lepault F, Gagnerault MC. Characterization of peripheral regulatory CD4 T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 2000; 164:2407.
  • 7
    Szanya V, Ermann J, Taylor C et al. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002; 169:24615.
  • 8
    Pop SM, Wong CP, Culton DA, Clarke SH, Tisch R. Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J Exp Med 2005; 201:133346.
  • 9
    Belghith M, Bluestone JA, Barriot S et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9:12028.
  • 10
    Luo X, Yang H, Kim IS et al. Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation 2005; 79:10916.
  • 11
    Flaumenhaft R, Kojima S, Abe M et al. Activation of latent transforming growth factor β. Adv Pharmacol 1993; 24:5176.
  • 12
    Wallik SC, Figari IS, Morris RE et al. Immunoregulatory role of transforming growth factor β (TGF-β) in development of killer cells: comparison of active and latent TGF-β1. J Exp Med 1990; 172:177784.
  • 13
    Chen W, Frank ME, Jin W et al. TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14:71525.
  • 14
    Calcinaro F, Dionisi S, Marinaro M et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005; 48:156575.
  • 15
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 (Suppl. 1):S438.
  • 16
    Casu A, Pascutto C, Bernardinelli L et al. Type 1 diabetes among Sardinian children is increasing: the Sardinian diabetes register for children aged 0–14 years (1989–1999). Diabetes Care 2004; 27:16239.
  • 17
    Pastore M, Bazzigaluppi E, Bonfanti R et al. Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives. Diabetes Care 1998; 21:144550.
  • 18
    Locatelli M, Songini M, Bottazzo GF. IDDM Sardinia Project: a study model on the etiopathogenesis of insulin-dependent diabetes mellitus and other autoimmune pathologies. Ann Ist Super Sanità 1999; 35:25363.
  • 19
    Vukkadapu SS, Belli JM, Ishii K et al. Dynamic interaction between T cell-mediated β-cell damage and β-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics 2005; 21:20111.
  • 20
    Von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing–remitting disease? Nat Rev Immunol 2007; 7:98894.
  • 21
    Bonifacio E, Hummel M, Walter M et al. IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care 2004; 11:2695700.
  • 22
    Gorsuch AN, Spencer KM, Lister J et al. Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981; 2:13635.
  • 23
    Buzzetti R, Galgani A, Petrone A et al. Genetic prediction of type 1 diabetes in a population with low frequency of HLA risk genotypes and low incidence of the diseases (the DIABFIN study). Diabetes Metab Res Rev 2004; 20:13743.